CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 89 enrolled
Drug / intervention
LFIT™ Femoral Heads With X3® Insertdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00510458
NCT00510458N/ACompleted

LFIT™ Anatomic CoCr Femoral Heads With X3® Polyethylene Insert Study - An Open Label, Prospective, Post-market, Multi-center Clinical Evaluation of the LFIT™ Anatomic CoCr Femoral Heads With X3® Inserts

Stryker Orthopaedics·interventional·Posted Aug 2, 2007·Updated Mar 12, 2018

In Brief

A clinical study evaluating LFIT™ Femoral Heads With X3® Insert for Arthroplasty, Replacement, Hip. Completed, enrolled 89 participants across 5 sites.

Detailed Summary

Total hip replacement surgery is considered to be a very successful surgical procedure for the treatment of degenerative joint disease. The purpose of the study is to evaluate a large size (36mm, 40mm or 44mm) femoral (hip) head called the LFIT™ Anatomic CoCr Femoral Head (Low Friction Ion Treatment). The large size femoral heads will be used with the Trident® X3® polyethylene (plastic) inserts and will be compared with a historical control. Study Hypothesis: The linear wear rate for hips implanted with the LFIT™ Anatomic CoCr Femoral Head is no worse than 0.08 mm wear per year at 5 years post-surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 2, 2007
Enrollment StartApr 1, 2007
Primary CompletionDec 1, 2016
TodayJul 2, 2026
Enrollment to primary: 9.7 yearsPosted 18.9 years ago

Interventions

LFIT™ Femoral Heads With X3® Insertdevice

LFIT™ Anatomic CoCr Femoral Heads With X3® Polyethylene Insert in total hip replacement